Electra Therapeutics, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on September 21, 2026, reporting the closing of its initial public offering and the adoption of amended and restated governance documents effective the same date.

Key Highlights

  • IPO closed: The company closed its initial public offering on September 21, 2026.
  • Shares offered: An aggregate of 23,333,334 shares of common stock were sold in the IPO.
  • Offering price: Shares were priced at $15.00 per share to the public.
  • Gross proceeds: Aggregate gross proceeds before deducting underwriting discounts, commissions, and estimated offering expenses were approximately $350.0 million.
  • Restated Certificate of Incorporation: The company filed an amended and restated certificate of incorporation with the Delaware Secretary of State on September 21, 2026, effective upon the IPO closing.
  • Restated Bylaws: Amended and restated bylaws were adopted effective September 21, 2026, also in connection with the IPO closing.

Electra Therapeutics IPO Closing and Governance Changes

According to the filing, Electra Therapeutics, Inc. (NASDAQ:ETRA) completed the closing of its initial public offering on September 21, 2026. The company sold 23,333,334 shares of common stock at a public offering price of $15.00 per share. The filing disclosed that aggregate gross proceeds were approximately $350.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the company.

In connection with the IPO closing, the company disclosed two amendments to its governing documents under Item 5.03 of the Form 8-K. On September 21, 2026, the company filed an amended and restated certificate of incorporation with the Secretary of State of the State of Delaware. The filing noted that the board of directors and stockholders had previously approved the restated certificate, with effectiveness conditioned on the IPO closing. On the same date, the company adopted amended and restated bylaws, which were similarly pre-approved by the board and stockholders to become effective upon closing.

The filing directed readers to the section titled "Description of Capital Stock" in the final prospectus filed with the SEC on September 18, 2026, pursuant to Rule 424(b) under the Securities Act of 1933, in connection with the Registration Statement on Form S-1 (File No. 333-298617), for further description of the restated certificate and bylaws. The amended and restated certificate of incorporation and bylaws were attached as Exhibits 3.1 and 3.2, respectively. The Form 8-K was signed by Quehuong (Kathy) Dong, Pharm.D., M.B.A., President and Chief Executive Officer.

What Was Disclosed

Electra Therapeutics reported the September 21, 2026 closing of its IPO, the sale of 23,333,334 common shares at $15.00 per share for approximately $350.0 million in gross proceeds, and the adoption of an amended and restated certificate of incorporation and bylaws effective the same date.